Sagent Pharmaceuticals Announces Launch of First Two Oncolytic Products: Fludarabine Phosphate for Injection, USP and Epirubicin Hydrochloride Injection
SCHAUMBURG, Ill., Aug. 5 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, today announced that it has launched fludarabine phosphate for injection, USP and epirubicin
hydrochloride injection. IMS data indicates the combined U.S. market...
High-Dosage of Epirubicin and Cyclophosphamide may cause AML
Adjuvant chemotherapy with epirubicin
and cyclophosphamide for early breast cancer// patients increased the risk of Acute myeloid leukemia or Myelodysplastic syndrome.
Recent study published in Journal of clinical oncology reports that early breast cancer patients undergoing chemotherapy with ...
Gene alterations associated with response to anthracycline therapy for breast cancer
... 2 gene.
Several studies have shown that women whose tumors have amplified HER2 derive benefit from regimens that include anthracyclines, such as epirubicin
and doxorubicin, while patients whose tumors lack such alteration do not. Scientists have hypothesized that this difference could be due to alteration...
How chemotherapy drugs block blood vessel growth, slow cancer spread
...reduced HIF-1's gene-activating ability by more than 99 percent. They tested other members of the anthracycline drug class and found that doxorubicin, epirubicin
and idarubicin also blocked HIF-1 activity. But further examination showed that both drug-treated and untreated cells contained similar amounts of HIF...
Biomarkers: What can they tell us
...ycline chemotherapy. Researchers analyzed 1,625 samples from NEAT (National epirubicin
Adjuvant Trial) and found that those patients with C17 polysomic tumors had significantly greater benefit from epirubicin
than those without, even when taking HER2 status into consideration. Resear...
India's Breast Cancer Drug Market Will Almost Double by 2012
...revalence, increasing wealth and growing disease awareness.
The report finds that docetaxel (Sanofi-Aventis's Taxotere, Indian products) and epirubicin
(Pfizer's Farmorubicin, Indian products) will continue to be the market leaders, but sales of trastuzumab and bevacizumab (Roche's Herceptin and Avast...
Also in the July 29 JNCI
...icin. New models can help physicians calculate the epirubicin
dose associated with a 5 percent risk of cardiotox...cologists frequently use anthracyclines, including epirubicin
and doxorubicin, to treat breast cancer patients. ...ggest that patients receive no more than 900 mg/m2 epirubicin
over the course of their cancer care.
In the c...
NovoCure presents results from breast cancer pilot study
...aboratory work with a single-arm human pilot trial to determine the safety and efficacy of the Novo-TTF with neo-adjuvant chemotherapy (doxorubicin or epirubicin
together with docetaxel) in locally advanced breast cancer patients. This study is under way. Neo-adjuvant refers to chemotherapy delivered in advanc...
New Taxotere(R) (docetaxel) Injection Concentrate Data to be Presented at the 30th Annual San Antonio Breast Cancer Symposium (SABCS)
*FEC : Fluorouracil 600mg/m squared, epirubicin
60 mg/m2 , and
Cyclophosphamide 600 mg/m2 q 3wk x 8
100 mg/m2 q3wk x 4 followed by Cyclophosphamide100...igned to evaluate concomitant Taxotere(R) and epirubicin
versus a standard French chemotherapy regimen (FEC...
Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
...udied prospectively to examine the efficacy of treatment by intra-arterial infusion of a chemotherapeutic agents consisting of etoposide, carboplatin, epirubicin
and pharmacokinetic modulating chemotherapy by 5-FU and enteric-coated tegafur/uracil by Ishikawa, et al.
The median survival time after the thera...